Nucleoside phosphoramidates

• US 8,957,045 B2
• Filed: 02/25/2013
• Issued: 02/17/2015
• Est. Priority Date: 12/23/2008
• Status: Active Grant

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Pharmasset LLC (Gilead Sciences Inc.)
• Inventors: Sofia, Michael Joseph, Du, Jinfa, Wang, Peiyuan, Nagarathnam, Dhanapalan
• Primary Examiner(s): McIntosh, III, Traviss C
• Application Number:
  US13/775,333
• Publication Number:
  US 20130225519A1
• Time in Patent Office: 722 Days
• Field of Search: None
• US Class Current: 514/48
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A nucleoside compound having activity against hepatitis C virus is disclosed.

Claims

1. A compound represented by formula I, or a stereoisomer, salt, or pharmaceutically acceptable salt thereof:

2. A pharmaceutical composition comprising a pharmaceutically acceptable medium and a compound according to claim 1.

3. A method of treating a subject infected with a virus selected from the group consisting of hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus and Japanese encephalitis virus which comprises administering to the subject a therapeutically effective amount of a compound according to claim 1.

4. The method of to claim 3 wherein the subject is infected with hepatitis C virus.

5. A method of treating a subject in need thereof, which comprises contacting at least one hepatitis C virus infected cell with at least one compound according to claim 1.

11. The compound of claim 1 wherein R⁸ is OCH₃.

12. The compound of claim 1 wherein R⁸ is OH.

13. A pharmaceutical composition comprising a pharmaceutically acceptable medium and a compound according to claim 11.

14. A pharmaceutical composition comprising a pharmaceutically acceptable medium and a compound according to claim 12.

15. A method of treating a subject infected with a virus selected from the group consisting of hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus and Japanese encephalitis virus which comprises administering to the subject a therapeutically effective amount of a compound according to claim 11.

16. The method of claim 15 wherein the subject is infected with hepatitis C virus.

17. A method of treating a subject in need thereof, which comprises contacting at least one hepatitis C virus infected cell with at least one compound according to claim 11.

18. A method of treating a subject infected with a virus selected from the group consisting of hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus and Japanese encephalitis virus which comprises administering to the subject a therapeutically effective amount of a compound according to claim 12.

19. The method of claim 18 wherein the subject is infected with hepatitis C virus.

20. A method of treating a subject in need thereof, which comprises contacting at least one hepatitis C virus infected cell with at least one compound according to claim 12.

6. A compound represented by formula I, or a stereoisomer thereof:

7. A pharmaceutical composition comprising a pharmaceutically acceptable medium and a compound according to claim 6.

8. A method of treating a subject infected with a virus selected from the group consisting of hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus and Japanese encephalitis virus which comprises administering to the subject a therapeutically effective amount of a compound according to claim 6.

9. The method of to claim 8 wherein the subject is infected with hepatitis C virus.

10. A method of treating a subject in need thereof, which comprises contacting at least one hepatitis C virus infected cell with at least one compound according to claim 6.